Nam RK - Search Results

1

Wallis CJ, Nam RK. Wallis CJ, et al. Among authors: nam rk. Urology. 2015 Mar;85(3):628. doi: 10.1016/j.urology.2014.11.040. Urology. 2015. PMID: 25733277 No abstract available.

2

Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 microG./L.

Yu H, Diamandis EP, Wong PY, Nam R, Trachtenberg J. Yu H, et al. J Urol. 1997 Mar;157(3):913-8. J Urol. 1997. PMID: 9072598 Clinical Trial.

3

Prostate specific antigen velocity as a measure of the natural history of prostate cancer: defining a 'rapid riser' subset.

Nam RK, Klotz LH, Jewett MA, Danjoux C, Trachtenberg J. Nam RK, et al. Br J Urol. 1998 Jan;81(1):100-4. doi: 10.1046/j.1464-410x.1998.00523.x. Br J Urol. 1998. PMID: 9467484

4

Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis.

Nam RK, Fleshner N, Rakovitch E, Klotz L, Trachtenberg J, Choo R, Morton G, Danjoux C. Nam RK, et al. J Urol. 1999 May;161(5):1521-4. J Urol. 1999. PMID: 10210387

5

Comparison of molecular and conventional strategies for followup of superficial bladder cancer using decision analysis.

Nam RK, Redelmeier DA, Spiess PE, Sampson HA, Fradet Y, Jewett MA. Nam RK, et al. J Urol. 2000 Mar;163(3):752-7. J Urol. 2000. PMID: 10687970

6

Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression.

Nam RK, Elhaji Y, Krahn MD, Hakimi J, Ho M, Chu W, Sweet J, Trachtenberg J, Jewett MA, Narod SA. Nam RK, et al. J Urol. 2000 Aug;164(2):567-72. J Urol. 2000. PMID: 10893645

7

V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression.

Nam RK, Toi A, Vesprini D, Ho M, Chu W, Harvie S, Sweet J, Trachtenberg J, Jewett MA, Narod SA. Nam RK, et al. Urology. 2001 Jan;57(1):199-204. doi: 10.1016/s0090-4295(00)00928-6. Urology. 2001. PMID: 11164181

8

The ten-year rule revisited: accuracy of clinicians' estimates of life expectancy in patients with localized prostate cancer.

Krahn MD, Bremner KE, Asaria J, Alibhai SM, Nam R, Tomlinson G, Jewett MA, Warde P, Naglie G. Krahn MD, et al. Urology. 2002 Aug;60(2):258-63. doi: 10.1016/s0090-4295(02)01712-0. Urology. 2002. PMID: 12137823

9

Delay in surgical therapy for clinically localized prostate cancer and biochemical recurrence after radical prostatectomy.

Nam RK, Jewett MA, Krahn MD, Robinette MA, Tsihlias J, Toi A, Ho M, Evans A, Sweet J, Trachtenberg J. Nam RK, et al. Can J Urol. 2003 Jun;10(3):1891-8. Can J Urol. 2003. PMID: 12892576

10

Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy.

Klotz LH, Goldenberg SL, Jewett MA, Fradet Y, Nam R, Barkin J, Chin J, Chatterjee S; Canadian Uro-Oncology Group. Klotz LH, et al. J Urol. 2003 Sep;170(3):791-4. doi: 10.1097/01.ju.0000081404.98273.fd. J Urol. 2003. PMID: 12913699 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

182 results

Search Page

Filters